Maternal Vascular Health Screening Before Pregnancy: Clinical Relevance, Mechanisms, and Evidence-Based Strategies

Abstract

Maternal vascular health significantly influences reproductive outcomes, yet systematic screening before pregnancy remains underutilized in clinical practice. This article reviews the epidemiological burden, pathophysiological underpinnings, risk stratification, clinical features, diagnostic frameworks, and evolving management strategies for vascular health assessment in women planning pregnancy. Integrating recent evidence and guideline recommendations, we highlight the importance of proactive vascular evaluation to optimize maternal and fetal outcomes, elucidating practical implications for clinicians and outlining future research priorities.

Introduction

Preconception care is increasingly recognized as a cornerstone of maternal-fetal medicine, with vascular health screening emerging as a critical component. Vascular dysfunction before conception predisposes women to adverse pregnancy outcomes such as preeclampsia, fetal growth restriction, miscarriage, and future cardiovascular disease. Despite the compelling evidence, pre-pregnancy vascular assessment is inconsistently implemented. This review synthesizes current knowledge on maternal vascular health screening before pregnancy, emphasizing its clinical utility, underlying mechanisms, and integration into routine care for women of reproductive age.

Epidemiology / Disease Burden

Globally, hypertensive disorders of pregnancy affect up to 10% of pregnancies, with preeclampsia alone accounting for approximately 2-8%. Subclinical vascular dysfunction, including endothelial impairment and arterial stiffness, is prevalent in women of childbearing age, particularly in those with risk factors such as obesity, diabetes, and a family history of cardiovascular disease. Maternal vascular abnormalities contribute to a significant proportion of maternal and perinatal morbidity and mortality, underscoring the imperative for early identification and intervention.

Pathophysiology

Vascular health in the preconception period is determined by complex interactions between genetic, metabolic, inflammatory, and environmental factors. Endothelial dysfunction, characterized by impaired nitric oxide bioavailability and increased oxidative stress, precedes clinically overt vascular disease. These changes disrupt vasodilation, promote inflammation, and facilitate a prothrombotic state. In the context of pregnancy, such dysfunction impairs trophoblastic invasion and remodeling of the spiral arteries, leading to maladaptive placental perfusion, hypertensive disorders, and fetal growth restriction. Recent studies implicate dysregulated angiogenic factors (e.g., sFlt-1, PlGF) and microvascular rarefaction as central mechanisms connecting preconception vascular health and pregnancy outcomes.

Risk Factors

Established risk factors for impaired maternal vascular health include advanced maternal age, obesity, metabolic syndrome, diabetes mellitus, chronic hypertension, autoimmune diseases (e.g., systemic lupus erythematosus, antiphospholipid syndrome), smoking, and a family history of cardiovascular or hypertensive disorders. Ethnic disparities are also noted, with higher prevalence among women of African, Hispanic, and Indigenous descent. Lifestyle factors such as sedentary behavior and poor dietary patterns further exacerbate vascular risk.

Clinical Features

Subclinical vascular dysfunction is typically asymptomatic before pregnancy, making proactive screening essential. However, subtle clinical manifestations may include elevated blood pressure, microalbuminuria, or signs of metabolic syndrome. A history of adverse pregnancy outcomes such as preeclampsia, preterm birth, or placental abruption increases the likelihood of underlying vascular pathology. Thorough clinical evaluation should encompass a detailed personal and family history, physical examination, and assessment of cardiovascular risk factors.

Diagnosis

Screening for maternal vascular health prior to conception involves a combination of clinical assessment and non-invasive investigations. Blood pressure measurement, urinalysis for proteinuria, and metabolic panel are foundational. Advanced modalities include assessment of endothelial function (e.g., flow-mediated dilation, peripheral arterial tonometry), pulse wave velocity, carotid intima-media thickness, and biomarkers such as high-sensitivity C-reactive protein and angiogenic factors. Integration of risk prediction models such as the Framingham risk score adapted for younger women may enhance stratification. Reproductive history and evaluation for inherited or acquired thrombophilias are also recommended in select populations.

Treatment & Management

Interventions for optimizing vascular health before pregnancy are multifaceted. Lifestyle modification including weight management, regular aerobic exercise, and a Mediterranean-style diet remains the cornerstone. Pharmacologic therapy may be indicated for underlying hypertension, diabetes, or dyslipidemia, with careful selection of agents compatible with future pregnancy (e.g., labetalol, methyldopa for hypertension). Antiplatelet therapy (low-dose aspirin) is advised in women at high risk for preeclampsia, initiated ideally before 16 weeks gestation. Management of underlying autoimmune or renal disease should be optimized with a multidisciplinary approach that includes preconception counseling and risk mitigation.

Recent Advances / Emerging Therapies

Recent advances in vascular health screening include the use of novel biomarkers (e.g., circulating microRNAs, endothelial progenitor cells) and sophisticated imaging modalities (e.g., 3D vascular ultrasound, cardiac MRI) to detect subclinical dysfunction with high sensitivity. Emerging therapies under investigation include targeted antioxidants, anti-inflammatory agents, and modulators of angiogenic pathways. Digital health interventions such as remote blood pressure monitoring and mobile health applications are being integrated into preconception care models to enhance accessibility and patient engagement. Ongoing clinical trials are evaluating the efficacy of early intervention strategies in reducing adverse pregnancy and long-term cardiovascular outcomes.

Guideline Recommendations

International guidelines, including those from the American College of Obstetricians and Gynecologists (ACOG), the International Society for the Study of Hypertension in Pregnancy (ISSHP), and the European Society of Cardiology (ESC), increasingly advocate for vascular risk assessment as part of routine preconception counseling, particularly in women with known risk factors. Recommendations emphasize individualized risk stratification, lifestyle optimization, control of modifiable comorbidities, and early initiation of preventive therapies where indicated. Integration of vascular screening into primary and reproductive healthcare is essential for widespread implementation.

Conclusion

Systematic vascular health screening before pregnancy offers a pivotal opportunity to identify and modify risk factors for adverse maternal and fetal outcomes. Advances in diagnostic modalities and a growing evidence base support the incorporation of vascular assessment into preconception care, especially for high-risk populations. Multidisciplinary collaboration, patient education, and alignment with evolving guidelines are key to translating these insights into improved reproductive and long-term cardiovascular health.